Siddhartha Kadia Buys 7,093 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Key Points

• CEO Siddhartha Kadia purchased 7,093 Mesa Laboratories shares at an average price of $112.80, investing approximately $800,090 in the company.
• Mesa Laboratories shares rose 2.0% to $108.19, while the company reported quarterly revenue of $60.14 million and earnings of $2.68 per share.
• The company declared a quarterly dividend of $0.16 per share, equivalent to $0.64 annually and a 0.6% yield. Analysts maintain a consensus “Hold” rating with a $110 price target.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) CEO Siddhartha Kadia bought 7,093 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was purchased at an average price of $112.80 per share, for a total transaction of $800,090.40. Following the acquisition, the chief executive officer owned 7,093 shares of the company's stock, valued at $800,090.40. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mesa Laboratories Trading Up 2.0%

Mesa Laboratories stock traded up $2.15 during trading hours on Monday, reaching $108.19. 77,359 shares of the company's stock were exchanged, compared to its average volume of 147,914. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. The firm's 50 day simple moving average is $100.64 and its 200 day simple moving average is $96.07. Mesa Laboratories, Inc. has a twelve month low of $58.83 and a twelve month high of $115.52. The firm has a market capitalization of $605.40 million, a PE ratio of 128.81 and a beta of 0.92.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The company had revenue of $60.14 million for the quarter.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories's payout ratio is presently 76.19%.

Hedge Funds Weigh In On Mesa Laboratories

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock worth $364,000 after purchasing an additional 143 shares during the period. American Century Companies Inc. grew its position in Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier's stock worth $1,265,000 after buying an additional 194 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Mesa Laboratories by 30.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 243 shares during the last quarter. Deutsche Bank AG increased its position in shares of Mesa Laboratories by 5.9% in the fourth quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier's stock worth $349,000 after purchasing an additional 248 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on MLAB shares. Weiss Ratings raised shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a research report on Friday. Finally, Wall Street Zen lowered shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Mesa Laboratories has a consensus rating of "Hold" and a consensus price target of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source